LABP

Landos Biopharma, Inc. [LABP] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

LABP Stock Summary

Top LABP Correlated Resources

LABP


Top 10 Correlated ETFs

LABP


Top 10 Correlated Stocks

LABP


In the News

12:17 28 Mar 2024 LABP

Why Is Landos Biopharma (LABP) Stock Up 168% Today?

Landos Biopharma (NASDAQ: LABP ) stock is on the rise Monday after the company announced an acquisition deal with AbbVie (NYSE: ABBV ). AbbVie is acquiring Landos Biopharma for $20.42 per share in cash.

08:39 28 Mar 2024 LABP

AbbVie to buy Landos to expand pipeline of immunity-related illnesses

AbbVie said on Monday it would acquire drug developer Landos Biopharma for up to $212 million as the Humira-maker aims to expand its pipeline of medicines to treat immune system-related illnesses.

08:00 28 Mar 2024 LABP

Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn's and Colitis Organisation

Six Presentations Highlight Landos' Leadership in Targeting Immunometabolic Pathways as Novel Treatments for Autoimmune Diseases with Focus on Ulcerative Colitis Six Presentations Highlight Landos' Leadership in Targeting Immunometabolic Pathways as Novel Treatments for Autoimmune Diseases with Focus on Ulcerative Colitis

08:00 28 Mar 2024 LABP

Landos Biopharma to Present at the American College of Gastroenterology 2023 Annual Scientific Meeting

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will present additional findings from its Phase 1b study of NX-13 for the treatment of ulcerative colitis (UC), including detailed results on the rapid symptomatic relief and improvement in multiple clinical biomarkers observed in the study, at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting, being held October 20-25 in Vancouver, Canada.

04:15 28 Mar 2024 LABP

Landos Biopharma to Present at the 2023 Jefferies Healthcare Conference

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will participate at the Jefferies Healthcare Conference, to be held from June 7-9, 2023 in New York, NY.

01:00 28 Mar 2024 LABP

3 Top Biotech Penny Stocks Under $3 To Watch Right Now

Biotech penny stocks to watch right now. The post 3 Top Biotech Penny Stocks Under $3 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

09:02 28 Mar 2024 LABP

5 Biotech Stocks Set to Outpace Q1 Earnings Estimates

Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

10:59 28 Mar 2024 LABP

Landos Biopharma, Inc.'s (LABP) CEO Tim Mayleben on Q3 2021 Results - Earnings Call Transcript

Landos Biopharma, Inc.'s (LABP) CEO Tim Mayleben on Q3 2021 Results - Earnings Call Transcript

09:57 28 Mar 2024 LABP

Should You Buy Landos Biopharma (LABP) Ahead of Earnings?

Landos Biopharma (LABP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

07:00 28 Mar 2024 LABP

Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus

Phase 1 trial initiation expected before yearend with topline results in 1H 2022

LABP Financial details

Company Rating
Sell
Market Cap
24.4M
Income
-19.25M
Revenue
0
Book val./share
6.07
Cash/share
6.84
Dividend
-
Dividend %
-
Employees
22
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-1.42
Forward P/E
-16.51
PEG
-0.05
P/S
-
P/B
0.72
P/C
3.14
P/FCF
-0.71
Quick Ratio
7.63
Current Ratio
7.77
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.39
EPS next Y
-1.3
EPS next Q
-0.89
EPS this Y
-99.63%
EPS next Y
-61.65%
EPS next 5Y
-68.14%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
49.21%
-
-
-
-
SMA20
150%
SMA50
275%
SMA100
275%
Inst Own
23.93%
Inst Trans
0.61%
ROA
-45%
ROE
-46%
ROC
-0.6%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
3.12M
Shs Float
2.81M
-
-
-
-
Target Price
-
52W Range
2.43-8.08
52W High
+168.25%
52W Low
+973%
RSI
97
Rel Volume
4.56
Avg Volume
10.26K
Volume
46.79K
Perf Week
207.01%
Perf Month
293.04%
Perf Quarter
492.82%
Perf Half Y
458.85%
-
-
-
-
Beta
-0.41
-
-
Volatility
6.18%, 5.59%
Prev Close
0.47%
Price
21.46
Change
0.28%

LABP Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
004.7900
Net income per share
-4.27-7.7-10.18-0.940
Operating cash flow per share
-3.03-5.86-7.21-1.140
Free cash flow per share
-3.08-5.91-7.32-1.140
Cash per share
15.327.1824.21.10.01
Book value per share
-7.84-13.7920.310.970.01
Tangible book value per share
-7.84-13.7920.310.970.01
Share holders equity per share
-7.84-13.7920.310.970.01
Interest debt per share
0.0900-0.010
Market cap
391.42M469.96M180.28M201.27M22.97B
Enterprise value
381.61M467.54M171.98M164.63M22.93B
P/E ratio
-28.1-15.59-4.72-5.3-1.05K
Price to sales ratio
0010.0200
POCF ratio
-39.64-20.47-6.66-4.4-1.12K
PFCF ratio
-39.02-20.31-6.56-4.4-1.12K
P/B Ratio
-15.3-8.72.365.14722.52
PTB ratio
-15.3-8.72.365.14722.52
EV to sales
009.5500
Enterprise value over EBITDA
-29.29-15.54-4.43-4.06-1.01K
EV to operating cash flow
-38.65-20.36-6.36-3.6-1.12K
EV to free cash flow
-38.04-20.2-6.25-3.6-1.12K
Earnings yield
-0.04-0.06-0.21-0.190
Free cash flow yield
-0.03-0.05-0.15-0.230
Debt to equity
00000
Debt to assets
00000
Net debt to EBITDA
0.750.080.210.91.65
Current ratio
16.562.715.557.396.09
Interest coverage
-43.720070.30
Income quality
0.730.760.71.170.93
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
000.8500
Research and developement to revenue
002.3100
Intangibles to total assets
00000
Capex to operating cash flow
0.020.010.0200
Capex to revenue
00-0.0200
Capex to depreciation
-1.53-1.32-2.24-0.010
Stock based compensation to revenue
000.2300
Graham number
27.4548.8768.194.540.02
ROIC
0.540.57-0.51-1-0.71
Return on tangible assets
-0.28-0.99-0.41-0.84-0.58
Graham Net
-8-14.1519.770.950
Working capital
47.08M18.85M75.54M39.13M31.79M
Tangible asset value
-25.58M-54.02M76.27M39.13M31.79M
Net current asset value
-25.95M-54.46M75.54M39.13M31.79M
Invested capital
00000
Average receivables
1.05M77.5K77K00
Average payables
1.87M5.33M10.76M8.17M2.41M
Average inventory
0699K699K00
Days sales outstanding
00000
Days payables outstanding
7.26K22.93K24.04K2.17K0
Days of inventory on hand
03.72K000
Receivables turnover
00000
Payables turnover
0.050.020.020.170
Inventory turnover
00.1000
ROE
0.540.56-0.5-0.97-0.69
Capex per share
-0.05-0.05-0.1200

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-1.98-0.96-0.86-0.63-0.94
Operating cash flow per share
-1.88-0.92-1.26-0.82-0.36
Free cash flow per share
-1.92-0.92-1.26-0.82-0.36
Cash per share
11.9211.037.717.216.84
Book value per share
10.939.727.256.976.07
Tangible book value per share
10.939.727.256.976.07
Share holders equity per share
10.939.727.256.976.07
Interest debt per share
0.02-0.75-0.070.09-0.11
Market cap
26.17M20.13M19.32M26.13M24.09M
Enterprise value
-2.71M-16.51M-25.92M-17.91M-18.32M
P/E ratio
-0.82-1.3-0.86-1.67-1.03
Price to sales ratio
00000
POCF ratio
-3.46-5.44-2.37-5.11-10.81
PFCF ratio
-3.39-5.43-2.37-5.11-10.81
P/B Ratio
0.590.510.410.60.64
PTB ratio
0.590.510.410.60.64
EV to sales
00000
Enterprise value over EBITDA
0.352.5444.073.52
EV to operating cash flow
0.364.463.173.518.22
EV to free cash flow
0.354.463.173.518.22
Earnings yield
-0.3-0.19-0.29-0.15-0.24
Free cash flow yield
-0.29-0.18-0.42-0.2-0.09
Debt to equity
00000
Debt to assets
00000
Net debt to EBITDA
3.695.636.9910.018.16
Current ratio
9.047.3912.315.357.77
Interest coverage
-116.852.1714.56-7.977.9
Income quality
0.960.711.351.30.38
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.020000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
22.0614.5211.869.9511.35
ROIC
-0.18-0.12-0.13-0.09-0.14
Return on tangible assets
-0.16-0.09-0.11-0.08-0.14
Graham Net
10.569.517.076.725.94
Working capital
44.01M39.13M47.02M43.27M37.66M
Tangible asset value
44.01M39.13M47.02M43.27M37.66M
Net current asset value
44.01M39.13M47.02M43.27M37.66M
Invested capital
00000
Average receivables
00000
Average payables
3.96M3.32M2.87M1.66M1.08M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.18-0.1-0.12-0.09-0.16
Capex per share
-0.030000

LABP Frequently Asked Questions

What is Landos Biopharma, Inc. stock symbol ?

Landos Biopharma, Inc. is a US stock , located in Blacksburg of Va and trading under the symbol LABP

What is Landos Biopharma, Inc. stock quote today ?

Landos Biopharma, Inc. stock price is $21.46 today.

Is Landos Biopharma, Inc. stock public?

Yes, Landos Biopharma, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap